Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1872033 | 0.98 | CYP2A6 (0.63) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL826569 | 0.94 | TDP1 (0.67) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL10350863 | 0.92 | HRH1 (0.68) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL10895097 | 0.92 | HRH1 (0.68) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL740922 | 0.92 | HRH1 (0.68) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL742233 | 0.92 | HRH1 (0.68) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL10349750 | 0.92 | HRH1 (0.68) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL2240266 | 0.87 | — | — | |
| SCHEMBL29485675 | 0.87 | TDP1 (0.80) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL29485677 | 0.87 | CYP2A6 (0.76) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | claimed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | claimed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | claimed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| CN-109689640-A | It can be used as the compound of immunomodulator | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| WO-2016042280-A1 | CONJUGATES OF AMINO ACID-PYRIDINE/PYRIDINIUM AND USES THEREOF AS BIOCIDAL AGENTS | Université de Nice Sophia Antipolis (FR) | 2016-03-24 | — | — | WO | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
| US-5116986-A | HETEROAROMATIC AMINE DERIVATIVES | DR. KARL THOMAE GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-5089497-A | Dopaminergic agents | WARNER-LAMBERT COMPANY (US) | 1992-02-18 | — | — | US | disclosed |
| US-4948795-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4912115-A | Cardiovascular disorders | DR. KARL THOMAE GMBH (DE) | 1990-03-27 | — | — | US | disclosed |
| EP-0350145-A2 | Pyridylthiazolidine carboxamide derivatives and their intermediates and production of both | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-01-10 | — | — | EP | disclosed |
| EP-0173041-B1 | 2-SUBSTITUTED-1,3-PROPYLIDENEDIPHOSPHONATE DERIVATIVES, THE PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYMPHAR S.A. (CH) | 1988-11-30 | — | — | EP | disclosed |
| EP-0269968-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-06-08 | — | — | EP | disclosed |
| US-4696920-A | CARDIOVASCULAR DISORDERS | SYMPHAR S.A. (CH) | 1987-09-29 | — | — | US | disclosed |
| EP-0173041-A1 | 2-Substituted-1,3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them | SYMPHAR S.A. (CH) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | CYP2A6 4190/4885TDP1 2453/4885L3MBTL1 4696/4885 |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | PDXK, RAD54L, CDKL5 | CYP2A6 2878/4885TDP1 3812/4885L3MBTL1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.